TG Therapeutics Inc

Research TG Therapeutics Inc (TGTX) on Bullrun: valuation model: 4.3% undervalued, market cap USD 8.53B, P/E 19.4. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerTGTX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal4.3% undervalued
• Market capUSD 8.53B
• P/E19.4
• Financial periodFY2025
• RevenueUSD 616.29M
• Revenue growth87.3%
• Net incomeUSD 447.20M
• Free cash flow-USD 24.99M
• Gross margin83.7%

Valuation Snapshot

Bullrun's latest valuation model marks TG Therapeutics Inc as 4.3% undervalued; latest market cap is USD 8.53B; P/E is 19.4.

About TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Frequently asked questions

Is TG Therapeutics Inc overvalued or undervalued?

Bullrun's valuation model currently marks TG Therapeutics Inc as 4.3% undervalued.

What is TG Therapeutics Inc's market cap?

TG Therapeutics Inc's market capitalization is USD 8.53B.

What is TG Therapeutics Inc's P/E ratio?

TG Therapeutics Inc's price-to-earnings (P/E) ratio is 19.4.

What does TG Therapeutics Inc do?

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.